Pharming (PHAR) Receivables (2019 - 2026)
Pharming (PHAR) posted Receivables of $60.0 million for Q1 2026, up 6.0% on a QoQ basis from $56.6 million in Q4 2025, and up 26.42% year-over-year from $47.5 million in Q1 2025.
Pharming (PHAR) Receivables (2019 - 2026) Analysis & Trends
Pharming's Receivables history runs 8 years deep, the most recent figure standing at $60.0 million for Q1 2026.
- Quarterly Receivables rose 26.42% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.0 million (up 26.42% YoY) and the FY2025 annual result came in at $56.6 million, changed 0.38% from the prior year.
- Receivables was $60.0 million for Q1 2026 at Pharming, up from $56.6 million in the prior quarter.
- Across five years, Receivables topped out at $60.0 million in Q1 2026 and bottomed at $28828.0 in Q3 2022.
- A 5-year average of $41.4 million and a median of $43.6 million in 2025 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables plunged 99.91% — and 2023, when it soared 140461.26%.
- Pharming's Receivables stood at $28.7 million in 2022, then soared by 68.09% to $48.3 million in 2023, then climbed by 16.8% to $56.4 million in 2024, then advanced by 0.38% to $56.6 million in 2025, then climbed by 6.0% to $60.0 million in 2026.
- Business Quant data shows PHAR's Receivables at $60.0 million in Q1 2026, $56.6 million in Q4 2025, and $43.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn | 60.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.03 Mn |
| Dec 31, 2025 | 56.64 Mn |
| Sep 30, 2025 | 43.61 Mn |
| Jun 30, 2025 | 53.33 Mn |
| Mar 31, 2025 | 47.49 Mn |
| Dec 31, 2024 | 56.42 Mn |
| Sep 30, 2024 | 48.20 Mn |
| Jun 30, 2024 | 51.12 Mn |
| Mar 31, 2024 | 38.70 Mn |
| Dec 31, 2023 | 48.30 Mn |
| Sep 30, 2023 | 40.52 Mn |
| Jun 30, 2023 | 33.16 Mn |
| Mar 31, 2023 | 32.93 Mn |
| Dec 31, 2022 | 28.74 Mn |
| Sep 30, 2022 | 28,828.00 |
| Jun 30, 2022 | 32.88 Mn |
| Mar 31, 2022 | 31.45 Mn |
| Dec 31, 2021 | 30,262.61 |
| Sep 30, 2021 | 32.81 Mn |
| Jun 30, 2021 | 37.55 Mn |